A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2028-10-18
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).